Liminatus Pharma Inc. (NASDAQ:LIMN – Get Free Report) saw a significant decrease in short interest during the month of April. As of April 30th, there was short interest totaling 1,083,465 shares, a decrease of 45.5% from the April 15th total of 1,989,468 shares. Approximately 2.4% of the shares of the stock are sold short. Based on an average daily volume of 2,651,998 shares, the short-interest ratio is presently 0.4 days.
Liminatus Pharma Trading Down 2.2%
Liminatus Pharma stock traded down $0.00 during midday trading on Friday, reaching $0.18. 754,434 shares of the company were exchanged, compared to its average volume of 848,027. The firm’s 50-day simple moving average is $0.20 and its 200-day simple moving average is $0.61. Liminatus Pharma has a 1 year low of $0.16 and a 1 year high of $33.66.
Liminatus Pharma (NASDAQ:LIMN – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.03) earnings per share (EPS) for the quarter.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on Liminatus Pharma
Liminatus Pharma Company Profile
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Read More
- Five stocks we like better than Liminatus Pharma
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
